Prazosin in the Treatment of PTSD

@article{Green2014PrazosinIT,
  title={Prazosin in the Treatment of PTSD},
  author={B. Green},
  journal={Journal of Psychiatric Practice},
  year={2014},
  volume={20},
  pages={253–259}
}
  • B. Green
  • Published 2014
  • Psychology, Medicine
  • Journal of Psychiatric Practice
Posttraumatic stress disorder (PTSD) often follows a chronic course, and the disorder is resistant to treatment with antidepressants and cognitive-behavioral therapy in a proportion of patients. Prazosin, an a1-adrenoceptor blocker, has shown some promise in treating chronic PTSD. A review of this literature was conducted via a search of MEDLINE and SUMMON, using keywords such as PTSD, prazosin, treatment, and resistance. At least 10 clinical studies of prazosin in the treatment of PTSD… Expand
Using Prazosin to Treat Posttraumatic Stress Disorder and Associations: A Systematic Review
TLDR
Several clinical studies demonstrated the relevant role of prazosin for treating PTSD symptoms, and it is shown that this drug is an affordable and cost-effective pharmacological option compared to other drugs used to treat PTSD. Expand
Prazosin for treating sleep disturbances in adults with posttraumatic stress disorder: a systematic review and meta-analysis of randomized controlled trials.
TLDR
Prazosin showed medium-to-large and statistically significant effects on PTSD symptoms in general and sleep disturbances in particular, and should be interpreted with caution given the limited total number of participants and the limitations induced by the majority of participants being male and noncivilian. Expand
Two Case Reports on Use of Prazosin for Drug Dreams
TLDR
Both patients with substance use disorder experiencing drug dreams which resolved after the addition of prazosin during an acute psychiatric hospitalization reported an alleviation of their DD after the medication was initiated, similar to the effect on nightmares in PTSD. Expand
Treatment Resistance in Post-traumatic Stress Disorder
TLDR
It is argued that a staging model of PTSD will lead to more systematic research into the treatment of PTSD and assist in strategies to develop treatment resistance such as a personalised medicine approach. Expand
Meta-analysis of the efficacy and safety of prazosin versus placebo for the treatment of nightmares and sleep disturbances in adults with posttraumatic stress disorder
TLDR
PTSD-related nightmares, sleep disturbances, and overall illness severity showed a significant response to treatment with prazosin, with careful dose titration. Expand
Treatments for Post-traumatic Stress Disorder: Pharmaceutical and Electrophysiologic Considerations
TLDR
While the evidence for combined psychotherapy and either pharmacological or physiological treatments is only now emerging, some of these modalities appear promising. Expand
Peer Review #2 of "Effects of chronic prazosin, an alpha-1 adrenergic antagonist, on anxiety-like behavior and cortisol levels in a chronic unpredictable stress model in zebrafish (Danio rerio) (v0.2)"
TLDR
The zebrafish model was utilized to determine behavioral and biological changes induced by chronic unpredictable stress and how these effects could be modulated by chronic prazosin treatment, and results indicated that 7d of CUS increased anxiety-like behavior in the novel tank test and decreased basal levels of cortisol, suggesting prazoin-induced relief from anxiety in stress-related conditions may involve an alternative mechanism other than by normalizing neuroendocrine dysfunction. Expand
Effects of chronic prazosin, an alpha-1 adrenergic antagonist, on anxiety-like behavior and cortisol levels in a chronic unpredictable stress model in zebrafish (Danio rerio)
TLDR
The zebrafish model was utilized to determine behavioral and biological changes induced by chronic unpredictable stress and how these effects could be modulated by chronic prazosin treatment, and results indicated that 7d of CUS increased anxiety-like behavior in the novel tank test and decreased basal levels of cortisol, suggesting prazoin-induced relief from anxiety in stress-related conditions may involve an alternative mechanism other than by normalizing neuroendocrine dysfunction. Expand
The preclinical profile of brexpiprazole: what is its clinical relevance for the treatment of psychiatric disorders?
TLDR
Brexpiprazole is a serotonin–dopamine activity modulator in clinical development for schizophrenia, adjunctive treatment of major depressive disorder, agitation in Alzheimer’s disease and post-traumatic stress disorder and has shown robust antipsychotic, antidepressant-like and anxiolytic activities in animal models. Expand
Recent Advancements in Treating Sleep Disorders in Co-Occurring PTSD
TLDR
Targeted treatment of sleep disorders in the context of PTSD offers a unique and underutilized opportunity to advance clinical care and research. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 30 REFERENCES
Preliminary Findings Concerning the Use of Prazosin for the Treatment of Posttraumatic Nightmares in a Refugee Population
TLDR
Preliminary support for the use of prazosin in targeting reduction of trauma-related nightmares and promoting improvement of global clinical status within an international sample of severely traumatized refugee patients is provided. Expand
Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: a placebo-controlled study.
TLDR
These data support the efficacy of prazosin for nightmares, sleep disturbance, and other PTSD symptoms. Expand
Prazosin Versus Quetiapine for Nighttime Posttraumatic Stress Disorder Symptoms in Veterans: An Assessment of Long-Term Comparative Effectiveness and Safety
TLDR
Prazosin should be used first-line for treating nighttime PTSD symptoms in a veteran population because of similar rate of short-term effectiveness, superior long- term effectiveness, and lower incidence of events leading to discontinuation, compared with quetiapine. Expand
Noradrenergic dysfunction and the psychopharmacology of posttraumatic stress disorder
TLDR
Studies of central noreadrenergic hyperactivity under both basal and challenge conditions are reviewed and the evidence for these derangements as potential psychopharmacologic targets in patients with PTSD is explored. Expand
Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military service-related PTSD: a randomized trial.
TLDR
Among patients with military-related PTSD with SRI-resistant symptoms, 6-month treatment with risperidone compared with placebo did not reduce PTSD symptoms and showed no significant difference in CAPS score. Expand
Prazosin Effects on Objective Sleep Measures and Clinical Symptoms in Civilian Trauma Posttraumatic Stress Disorder: A Placebo-Controlled Study
TLDR
Prazosin reductions of nighttime PTSD symptoms in civilian trauma PTSD are accompanied by increased total sleep time, REMSleep time, and mean REM period duration in the absence of a sedative-like effect on sleep onset latency. Expand
Prazosin Reduces Trauma-Related Nightmares in Older Men with Chronic Posttraumatic Stress Disorder
TLDR
Nine older men with chronic PTSD secondary to military or Holocaust trauma were prescribed the lipophilic alpha-1 adrenergic antagonist prazosin for treatment-resistant trauma-related nightmares and it substantially reduced nightmares and moderately or markedly reduced overall PTSD severity. Expand
Daytime Prazosin Reduces Psychological Distress to Trauma Specific Cues in Civilian Trauma Posttraumatic Stress Disorder
TLDR
Daytime prazosin pretreatment reduced psychological distress specifically to trauma cues and may further reduce overall PTSD illness severity and distress. Expand
A Parallel Group Placebo Controlled Study of Prazosin for Trauma Nightmares and Sleep Disturbance in Combat Veterans with Post-Traumatic Stress Disorder
TLDR
Prazosin is an effective and well-tolerated treatment for trauma nightmares, sleep disturbance and global clinical status in veterans with chronic PTSD. Expand
A 5-Year Longitudinal Study of Posttraumatic Stress Disorder in Primary Care Patients
TLDR
The course of PTSD in a sample of primary care patients is chronic and Cox regression analyses indicated that baseline clinical variables did not have a significant relationship with probability of PTSD recovery, but time-varying models showed that the course of psychosocial impairment was a significant predictor of the likelihood of recovery from PTSD. Expand
...
1
2
3
...